PDE4: a novel target in the treatment of chronic obstructive pulmonary disease (Q37963175)

26 August 2017

PDE4: a novel target in the treatment of chronic obstructive pulmonary disease (English)

1 reference

chronic obstructive pulmonary disease

26 August 2017

0 references

author name string

J M Michalski

1

1 reference

26 August 2017

G Golden

2

1 reference

26 August 2017

J Ikari

3

1 reference

26 August 2017

S I Rennard

4

1 reference

26 August 2017

language of work or name

English

0 references

publication date

30 November 2011

1 reference

Clinical Pharmacology & Therapeutics

26 August 2017

1 reference

26 August 2017

91

1 reference

26 August 2017

1

1 reference

26 August 2017

134-142

1 reference

https://scigraph.springernature.com/pub.10.1038/clpt.2011.266

26 August 2017

0 references

cites work

Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′,5′-monophosphate phosphodiesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Silence of the limbs pharmacological symptomatic treatment of intermittent claudication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Phosphodiesterase isozymes: molecular targets for novel antiasthma agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

PDE4 cAMP-specific phosphodiesterases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

ERK2 mitogen-activated protein kinase binding, phosphorylation, and regulation of the PDE4D cAMP-specific phosphodiesterases. The involvement of COOH-terminal docking sites and NH2-terminal UCR regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Protein kinase A-dependent activation of PDE4 (cAMP-specific cyclic nucleotide phosphodiesterase) in cultured bovine vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Oxidative stress employs phosphatidyl inositol 3-kinase and ERK signalling pathways to activate cAMP phosphodiesterase-4D3 (PDE4D3) through multi-site phosphorylation at Ser239 and Ser579.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Phosphorylation of cAMP-specific PDE4A5 (phosphodiesterase-4A5) by MK2 (MAPKAPK2) attenuates its activation through protein kinase A phosphorylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Selective SUMO modification of cAMP-specific phosphodiesterase-4D5 (PDE4D5) regulates the functional consequences of phosphorylation by PKA and ERK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Arrestin times for compartmentalised cAMP signalling and phosphodiesterase-4 enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Mapping binding sites for the PDE4D5 cAMP-specific phosphodiesterase to the N- and C-domains of beta-arrestin using spot-immobilized peptide arrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Phosphodiesterase 4D and protein kinase a type II constitute a signaling unit in the centrosomal area

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Compartmentalization of cAMP-dependent signaling by phosphodiesterase-4D is involved in the regulation of vasopressin-mediated water reabsorption in renal principal cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Interaction with receptor for activated C-kinase 1 (RACK1) sensitizes the phosphodiesterase PDE4D5 towards hydrolysis of cAMP and activation by protein kinase C

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Ndel1 alters its conformation by sequestering cAMP-specific phosphodiesterase-4D3 (PDE4D3) in a manner that is dynamically regulated through Protein Kinase A (PKA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Interaction between LIS1 and PDE4, and its role in cytoplasmic dynein function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Signaling from beta1- and beta2-adrenergic receptors is defined by differential interactions with PDE4

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

In cardiac myocytes, cAMP elevation triggers the down-regulation of transcripts and promoter activity for cyclic AMP phosphodiesterase-4A10 (PDE4A10).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Are phosphodiesterase 4 inhibitors just more theophylline?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Subtype selectivity in phosphodiesterase 4 (PDE4): a bottleneck in rational drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Global burden of COPD: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Association of serotonin transporter gene variation with smoking, chronic obstructive pulmonary disease, and its depressive symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Bone mineral density in patients with chronic obstructive pulmonary disease who are candidates for lung transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Effect of cilomilast (Ariflo) on TNF-alpha, IL-8, and GM-CSF release by airway cells of patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Phosphodiesterase 4 inhibitor cilomilast inhibits fibroblast-mediated collagen gel degradation induced by tumor necrosis factor-alpha and neutrophil elastase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Trends in kidney transplantation over the past decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

Chemotherapeutic potential of phosphodiesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

7 January 2021

The cAMP-specific phosphodiesterase PDE4D3 is regulated by phosphatidic acid binding. Consequences for cAMP signaling pathway and characterization of a phosphatidic acid binding site

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

7 January 2021

Selective activation of rolipram-sensitive, cAMP-specific phosphodiesterase isoforms by phosphatidic acid

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

7 January 2021

Differential effects of PDE4 inhibitors on cortical neurons and T-lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

7 January 2021

Role of emphysema and airway obstruction in prognosis of lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

7 January 2021

A phosphodiesterase 4 inhibitor inhibits matrix protein deposition in airways in vitro

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

7 January 2021

In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.266

7 January 2021

Identifiers

DOI

10.1038/CLPT.2011.266

1 reference

Dimensions Publication ID

26 August 2017

0 references

1 reference